Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × ridaforolimus × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Other solid neoplasm 1 Lymphoid 1 Gynecologic 1 Gastrointestinal 1 Breast 1

Conditions

Breast Neoplasms 1

Interventions

Trastuzumab 222 Paclitaxel 189 Cyclophosphamide 151 Docetaxel 122 Letrozole 111 Capecitabine 111 Fulvestrant 104 Doxorubicin 97 Carboplatin 81 Bevacizumab 81 exemestane 75 Anastrozole 73 Lapatinib 69 Tamoxifen 66 Albumin-Bound Paclitaxel 58 Taxes 55 palbociclib 54 pembrolizumab 53 Gemcitabine 51 pertuzumab 47 eribulin 45 130-nm albumin-bound paclitaxel 40 Radiotherapy 37 Everolimus 37 Vinorelbine 36 Ado-Trastuzumab Emtansine 36 ixabepilone 32 pegfilgrastim 28 Magnetic Resonance Spectroscopy 27 Goserelin 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01605396 2019-03-25

MK-8669-064

Merck Sharp & Dohme LLC

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡